MER reports scientific consulting for Boehringer Ingelheim, Intercept Pharmaceuticals, Madrigal, NGM Biopharmaceuticals, Novo Nordisk, GSK, Sonic Incytes, Histoindex, Takeda, Echosens, and Cytodyn; and has received support for travel to symposia from GSK and Novo Nordisk. AK has received grants from EU Horizon 2020, Novo Nordisk Foundation, Innovationfund Denmark, Danish National Research Foundation, Region of Southern Denmark, and AstraZeneca; receives royalties from Gyldendal as a coauthor on a textbook of internal medicine; has received research support from Norgine, Siemens, Nordic Bioscience, AstraZeneca, and Echosens; has acted as a consultant for Consulting Takeda, Resalis Therapeutics, Zealand Pharma, and AlphaSights; has served as speaker for Novo Nordisk, Norgine, Siemens and Nordic Bioscience; has participated on advisory boards for Norgine, Siemens, Resalis Therapeutics, Boehringer Ingelheim, and Novo Nordisk; and is a board member and cofounder of Evidoall outside the submitted work. MI declares no competing interests.